15 completed, 3 recruiting, 3 unknown, 1 active not recruiting. 23 Phase 2, 6 Phase 1, 2 Phase 3.
Follow Neoplasm, Lymphatic Tissue: new trials by email Literature Review of Neoplasm, Lymphatic Tissue trials Research Report on Neoplasm, Lymphatic Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies Everolimus - Vascular Malformations, Arteriovenous Malformations | Phase 2 | Not yet recruiting | Yonsei University | 67 | 2026-04-01 | 2026-03-17 |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Alpelisib, Placebo - Lymphatic Malformations | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 232 | 2023-11-24 | 2026-10-09 |
| Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations PTX-022 - Microcystic Lymphatic Malformation | Phase 2 | Completed | Palvella Therapeutics, Inc. | 12 | 2022-01-13 | 2025-01-17 |
| Effect of Loratadine in Lymphangioleiomyomatosis Loratadine, Placebo 10mg/day added to rapamycin for 12 months - Lymphangioleiomyomatosis | Phase 2 | Unknown | Institut d'Investigació Biomèdica de Bellvitge | 62 | 2021-11-01 | 2022-01-27 |
| Feasibility of [11C]Acetate-PET in LAM and TSC [11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Active not recruiting | Brigham and Women's Hospital | 7 | 2021-08-30 | 2026-01-21 |
| Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Sirolimus, Resveratrol - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 25 | 2018-03-31 | 2023-02-01 |
| LAM Pilot Study With Imatinib Mesylate Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 18 | 2018-01-23 | 2020-06-16 |
| Discovery of Sirolimus Sensitive Biomarkers in Blood Sirolimus 2mg - Lymphangioleiomyomatosis | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 33 | 2017-12-04 | 2026-02-18 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) Nintedanib - Lymphangioleiomyomatosis | Phase 2 | Completed | IRCCS Multimedica | 30 | 2016-12-06 | 2022-09-28 |
| COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC Celecoxib - Lymphangioleiomyomatosis (LAM) | Phase 2 | Completed | Brigham and Women's Hospital | 12 | 2016-06-15 | 2022-01-20 |
| Safety of Simvastatin in LAM and TSC Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 10 | 2014-03-01 | 2020-08-25 |
| Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis albuterol inhaler, albuterol nebulizer, PFT - Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 100 | 2013-06-10 | 2026-11-12 |
| Letrozole for Lymphangioleiomyomatosis Letrozole, Placebo - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 17 | 2011-05-01 | 2024-04-17 |
| A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations Sildenafil - Lymphangioma | Phase 1 / Phase 2 | Completed | Stanford University | 7 | 2010-12-01 | 2015-06-19 |
| A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis Everolimus - Lymphangioleiomyomatosis | Phase 2 | Completed | Novartis Pharmaceuticals | 24 | 2010-01-01 | 2020-11-19 |
| Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies sirolimus - Kaposiform Hemangioendotheliomas, Tufted Angioma | Phase 2 | Completed | Denise Martin Adams | 61 | 2009-10-01 | 2026-01-06 |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM sirolimus - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 2 | Unknown | Cardiff University | 14 | 2005-10-01 | 2008-04-30 |
| RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 36 | 2005-08-01 | 2013-09-25 |
Showing 20 of 23. Sign in to see all of them.
Lymphangioleiomyomatosis (15) · Lymphangioma (7) · Tuberous Sclerosis (5) · Lymphatic Abnormalities (4) · Lymphangioma, Cystic (3) · Vascular Malformations (3) · Arteriovenous Malformations (2) · Ascites (1) · Chylothorax (1) · Chylous Ascites (1) · Dermatofibrosarcoma (1) · Fibrosarcoma (1) · Hemangioendothelioma (1) · Hemangioma (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Neoplasms (23) · Neoplasms by Histologic Type (23) · Hemic and Lymphatic Diseases (21) · Lymphatic Diseases (20) · Neoplasms, Connective and Soft Tissue (16) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Lymphoproliferative Disorders (15) · Perivascular Epithelioid Cell Neoplasms (15) · Lymphangiomyoma (14) · Congenital Abnormalities (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Nervous System Diseases (6) · Genetic Diseases, Inborn (5)
Sirolimus (6) · Everolimus (4) · Alpelisib (2) · Celecoxib (1) · Imatinib Mesylate (1) · Letrozole (1) · Loratadine (1) · Octreotide (1) · Picibanil (1) · Radiation Dose Hypofractionation (1) · Resveratrol (1) · Sildenafil Citrate (1) · Simvastatin (1) · Sugars (1) · carbon-11 acetate (1)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Brigham and Women's Hospital (2) · Children's Hospital Medical Center, Cincinnati (2) · Novartis Pharmaceuticals (2) · University of Cincinnati (2) · Cardiff University (1) · Denise Martin Adams (1) · IRCCS Multimedica (1) · Institut d'Investigació Biomèdica de Bellvitge (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Medical University of South Carolina (1) · Murdoch Childrens Research Institute (1) · Palvella Therapeutics, Inc. (1) · Stanford University (1) · University of Iowa (1)
United States (17) · Italy (3) · Australia (2) · France (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Czechia (1) · Germany (1) · Netherlands (1) · Poland (1) · Switzerland (1)
Joel Moss, M.D. (2) · Alfred T Lane, MD (1) · Carmen P Priolo, MD PhD (1) · Christopher Meinberg (1) · David J Kwiatkowski, MD PhD (1) · Denise M Adams, MD (1) · Francis X McCormack, MD (1) · Frank McCormack, MD (1) · John Bissler, MD (1) · John J. Bissler, M.D. (1) · Julian R Sampson, DM (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Maria Molina-Molina, MD, PhD (1) · Maryl Kreider, MD, MSCE (1) · Nishant Gupta, MD (1)
PMID 12172553, PMID 18184959, PMID 19117316, PMID 21410393, PMID 21482669, PMID 21525172, PMID 24556663, PMID 24591665, PMID 24656411, PMID 26113676, PMID 28570161, PMID 30672136, PMID 32060062, PMID 35852876, PMID 36642366, PMID 39489895, PMID 42194972
2023 (1), R21CA103486 (1), R34HL138235 (1), UL1TR000093 (1)